Faeth Therapeutics, Inc. (FTH)
Nasdaq: FTH · Pharmaceutical Preparations · Rockville, MD · filing with the SEC since 2020
Who owns Faeth Therapeutics, Inc.
As filed with the SECHolders of 5% or more
3
VK Services, LLC holds 10.2% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G filed Aug 14, 2026 says.
Directors and officers
11
report now, of 26 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
VK Services, LLC
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share
S2G Investments, LLC
SCHEDULE 13G · filed Jun 23, 2026 · Common Stock, $0.0001 par value per share
Suvretta Capital Management, LLC
SCHEDULE 13G · filed Jun 23, 2026 · Common Stock, par value $0.0001 per share
ICS Opportunities II LLC
SCHEDULE 13G/A · filed Jun 3, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 9.6% in May 15, 2026
Caligan Partners LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 9.4% in May 15, 2026
Trails Edge Capital Partners, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 9.9% in Feb 25, 2026
StemPoint Capital LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 9.9% in May 15, 2026
What FTH reports owning in othersstakes of 5% or more, and other ties
Faeth Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
10sales
23purchases
0sales on a scheduled plan
1people selling
$800,000sold, in dollars
$1.2Mbought, in dollars
Open-market trades on Form 4 from Nov 3, 2025 to Nov 3, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 3, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 46 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Peyer James | director | 10 | $800,000 | 0 | 0 | $0 |
| Cambrian Biopharma Inc | 10% owner | 10 | $800,000 | 0 | 0 | $0 |
| Ics Opportunities II LLC | 10% owner | 18 | $600,000 | 0 | 16 | $1.0M |
| Millennium Management LLC | 10% owner | 7 | $100,000 | 0 | 10 | $400,000 |
| Stephenson Brian C | Chief Financial Officer | 0 | $0 | 0 | 22 | $1.1M |
| Parikh Anand Kiran | President and CEO | 0 | $0 | 0 | 1 | $100,000 |